Table 3. Recommendation and quality of evidence table for HIV protease inhibitors/boosting agents and anti-malarial drugs.
| Protease Inhibitors & boosting agents | Cobi (with ATV or DRV) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ATV/r | DRV/r | FPV/r | IDV/r | LPV/r | NFV | RTV | SQV/r | TPV/r | ||
| Amodiaquine | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | ◊ (4) | □ (4) | □ (4) | □ (4) | ◊ (4) |
| Artemether | □ (4) | □ (2)* | □ (4) | □ (4) | □ (2)* | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) |
| Artesunate | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (1)* | □ (4) | □ (4) | ◊ (4) |
| Atovaquone | □ (3)* | □ (4) | □ (4) | □ (4) | □ (2)* | □ (4) | □ (4)* | □ (4)* | □ (4) | ◊ (4) |
| Chloroquine | □ (4) | ◊ (4) | ◊ (4) | ◊ (4) | □ (4) | ◊ (4) | ◊ (4) | ○ (4) | ◊ (4) | ◊ (4) |
| Clindamycin | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) |
| Dihydroartemisinin | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) |
| Doxycycline | ◊ (3)* | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4)* | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Lumefantrine | □ (4) | □ (1)* | □ (4) | □ (4) | □ (2)* | □ (4) | □ (4) | □ (4) | ○ (4) | □ (4) |
| Mefloquine | □ (4) | □ (4) | □ (4) | □ (4)$ | □ (2)* | □ (4)* | □ (3)* | □ (4) | □ (4) | □ (4) |
| Piperaquine | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | □ (4) | ○ (4) | □ (4) | □ (4) |
| Primaquine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Proguanil | □ (3)* | □ (4) | □ (4) | □ (4) | □ (3)* | ◊ (4) | □ (4) | □ (4)* | □ (4) | ◊ (4) |
| Pyronaridine | ○ (2) | ○ (2) | ○ (2) | ○ (2) | ○ (2) | ○ (2) | ○ (1)* | ○ (2) | ○ (2) | □ (4) |
| Quinine | □ (4) | □ (4) | □ (4) | □ (4) | □ (2)* | □ (4) | □ (3)* | ○ (4) | □ (4) | □ (4) |
| Sulfadoxine/Pyrimethamine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |